SCHEMBL14775381

SCHEMBL14775381

CN(CCC(c1ccc(Cl)c(Cl)c1)N1CCOCC1)Cc1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 9/20 0.71
SLC6A4 P31645 7/20 0.71
SLC6A3 Q01959 6/20 0.71
SIGMAR1 Q99720 5/20 0.43
TACR2 P21452 1/20 0.41
ATM Q13315 1/20 0.41
CCR5 P51681 1/20 0.41
DPP4 P27487 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14775025 0.84 SLC6A4 (1.00) SLC6A2SLC6A4SLC6A3SIGMAR1TACR2
SCHEMBL14775299 0.83 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3
SCHEMBL14775175 0.82 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL14775011 0.82 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL14775544 0.81 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3
SCHEMBL14775376 0.80 SLC6A4 (0.64) SLC6A2SLC6A4SLC6A3
SCHEMBL14775432 0.79 SLC6A4 (0.86) SLC6A2SLC6A4SLC6A3SIGMAR1TACR2
SCHEMBL14775074 0.76 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3SIGMAR1
SCHEMBL14775515 0.76 SLC6A2 (0.48) SLC6A2SLC6A4ATM
SCHEMBL14775641 0.75 SLC6A2 (0.59) SLC6A2SLC6A4SLC6A3DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570409-B1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT SHANGHAI INST PHARM INDUSTRY (CN) 2015-07-08 EP claimed
US-8962621-B2 Aralkyl diamine derivatives and uses thereof as antidepressants SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2015-02-24 US claimed
US-20130072488-A1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2013-03-21 US claimed
EP-2570409-A1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT Shanghai Institute of Pharmaceutical Industry (CN) 2013-03-20 EP claimed
EP-2570409-B1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT SHANGHAI INST PHARM INDUSTRY (CN) 2015-07-08 EP disclosed
US-8962621-B2 Aralkyl diamine derivatives and uses thereof as antidepressants SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2015-02-24 US disclosed
US-20130072488-A1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2013-03-21 US disclosed
EP-2570409-A1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT Shanghai Institute of Pharmaceutical Industry (CN) 2013-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072488-A1 ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS MAOA, SLC6A2, MAOB SLC6A2 2/4885SLC6A4 5/4885SLC6A3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.